Development and Validation of Uv-Visible Spectrophometric and RP-HPLC Method for Simultaneous Estimation of Escitalopram oxalate and Etizolam in their Combined Dosage Form

Abstract

The combination of Escitalopram and Etizolam is mainly used for anti-psychotic therapy. The aim was to develop a UV and HPLC method for simultaneous estimation of both the drugs in the combined dosage form. In UV spectrophotmetric first order derivative spectroscopy was developed. First order spectra of ESC and ETI showed zero absorbance at 260.40 and at 243.80 nm respectively. So both ESC and ETI were estimated at wavelength 243.80 nm and 260.40 nm respectively. The calibration curve were linear in the range of 80 - 220 μg/ml for ESC (R2= 0.9969) and 8 – 50 μg/ml for ETI (R2=0.9939). In HPLC method Inertsil ODS-2 column (150 mm x 4.6mm x 5μm) with mobile phase containing Potassium dihydrogen phosphate (pH: 4.5): Acetonitrile: Methanol (65:30:5) was used and were detected at 240 nm. The linearity for ESC and ETI was in the range of150 – 650 μg/ml and 15 – 65 μg/ml respectively. All the other parameters were validated according to the ICH guidelines. High percentage recovery shows that there is no interference of excipients in the dosage form. The method was applied on pharmaceutical dosage form. The proposed methods was accurate, precise, sensitive and cost-effective that can be successfully applied to bulk drugs and pharmaceutical dosage forms.